ArticleMicrobial cell factories2015
Metabolic engineering of riboflavin production in Ashbya gossypii through pathway optimization.
Article in Microbial cell factories, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 62 citations in OpenAlex.
- Engineering Bacillus Subtilis for Efficient Biosynthesis of Riboflavin: Current Knowledge and Future Perspectives.Applied biochemistry and biotechnology · 2026Review
- Engineering riboflavin-overproducingSynthetic and systems biotechnology · 2026Article
- Biosynthesis, Regulation, and Biotechnological Production Strategies of Riboflavin (Vitamin BPharmaceuticals (Basel, Switzerland) · 2026Review
- Hog1 MAP kinase modulates early riboflavin accumulation under low-pH and saline conditions inFrontiers in microbiology · 2026Article
- First Report on Biosynthesis of Riboflavin by Microbacterium proteolyticum BWBTDIPO1 - Extraction, Characterization and Mechanistic Insight Via In-Silico Approach.Current microbiology · 2025Article
- Regulation of Riboflavin Biosynthesis in Microorganisms and Construction of the Advanced Overproducers of This Vitamin.International journal of molecular sciences · 2025Review
- Where Biology Meets Engineering: Scaling Up Microbial Nutraceuticals to Bridge Nutrition, Therapeutics, and Global Impact.Microorganisms · 2025Review
- Diverting organic waste from landfills via insect biomanufacturing using engineered black soldier flies (Hermetia illucens).Communications biology · 2024Review
- Driving the conversion of phytosterol to 9α-hydroxy-4-androstene-3,17-dione in Mycolicibacterium neoaurum by engineering the supply and regeneration of flavin adenine dinucleotide.Biotechnology for biofuels and bioproducts · 2023Article
- Riboflavin synthesis from gaseous nitrogen and carbon dioxide by a hybrid inorganic-biological system.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Genome Sequence and Analysis of the Flavinogenic YeastJournal of fungi (Basel, Switzerland) · 2022Article
- New Promoters for Metabolic Engineering ofJournal of fungi (Basel, Switzerland) · 2021Article
- Effects of sirtuins on the riboflavin production in Ashbya gossypii.Applied microbiology and biotechnology · 2021Article
- Strategies to Increase the Production of Biosynthetic Riboflavin.Molecular biotechnology · 2021Review
- Comparative Metagenomics Reveals Microbial Signatures of Sugarcane Phyllosphere in Organic Management.Frontiers in microbiology · 2021Article
- Genomic analysis of a riboflavin-overproducing Ashbya gossypii mutant isolated by disparity mutagenesis.BMC genomics · 2020Article
- Production of riboflavin and related cofactors by biotechnological processes.Microbial cell factories · 2020Review
- Production of Vitamin B2 (Riboflavin) by Microorganisms: An Overview.Frontiers in bioengineering and biotechnology · 2020Review
- Riboflavin Biosynthesis and Overproduction by a Derivative of the Human Gut CommensalFrontiers in microbiology · 2020Article
- Metabolic flux analysis in Ashbya gossypii usingMicrobial cell factories · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe industrial production of riboflavin mostly relies on the microbial fermentation of flavinogenic microorganisms and Ashbya gossypii is the main industrial producer of the vitamin. Accordingly, bioengineering strategies aimed at increasing riboflavin production in A. gossypii are highly valuable for industry.
resultsWe analyze the contribution of all the RIB genes to the production of riboflavin in A. gossypii. Two important metabolic rate-limiting steps that limit the overproduction of riboflavin have been found: first, low mRNA levels of the RIB genes hindered the overproduction of riboflavin; second, the competition of the AMP branch for purinogenic precursors also represents a limitation for riboflavin overproduction. Thus, overexpression of the RIB genes resulted in a significant increase in riboflavin yield. Moreover, both the inactivation and the underexpression of the ADE12 gene, which controls the first step of the AMP branch, also proved to have a positive effect on riboflavin production. Accordingly, a strain that combines both the overexpression of the RIB genes and the underexpression of the ADE12 gene was engineered. This strain produced 523 mg/L of riboflavin (5.4-fold higher than the wild-type), which is the highest titer of riboflavin obtained by metabolic engineering in A. gossypii so far.
conclusionsRiboflavin production in A. gossypii is limited by a low transcription activity of the RIB genes. Flux limitation towards AMP provides committed substrate GTP for riboflavin overproduction without detrimental effects on biomass formation. A multiple-engineered Ashbya strain that produces up to 523 mg/L of riboflavin was generated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.